Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 12/20 | 0.61 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | GAK | O14976 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2592996 | 0.89 | RIPK2 (0.65) | RIPK1RIPK2RIPK3KCNH2KDR | |
| SCHEMBL2589387 | 0.89 | RIPK2 (0.68) | RIPK1RIPK2RIPK3KCNH2KDR | |
| SCHEMBL2595405 | 0.86 | RIPK2 (0.64) | RIPK1RIPK2RIPK3KCNH2KDR | |
| SCHEMBL2595045 | 0.82 | RIPK1 (0.62) | RIPK1RIPK2RIPK3KCNH2KDR | |
| SCHEMBL2595976 | 0.78 | RIPK2 (0.77) | RIPK1RIPK2RIPK3KCNH2KDR | |
| SCHEMBL2591752 | 0.78 | RIPK2 (0.67) | RIPK1RIPK2RIPK3KCNH2KDR | |
| SCHEMBL600919 | 0.77 | RIPK2 (0.74) | RIPK1RIPK2RIPK3KCNH2KDR | |
| SCHEMBL2595306 | 0.76 | RIPK2 (1.00) | RIPK1RIPK2RIPK3KDRTGFBR1 | |
| SCHEMBL29638044 | 0.76 | RIPK2 (1.00) | RIPK1RIPK2RIPK3KDRTGFBR1 | |
| SCHEMBL12180671 | 0.76 | RIPK2 (0.66) | RIPK1RIPK2RIPK3KCNH2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566477-B1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-09-02 | — | — | EP | claimed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | claimed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| EP-2566477-B1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-09-02 | — | — | EP | disclosed |
| EP-2566477-B1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-09-02 | — | — | EP | disclosed |
| EP-2566477-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | disclosed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | disclosed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | disclosed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | RIPK1 410/4885RIPK2 326/4885RIPK3 421/4885 |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | RIPK1 410/4885RIPK2 326/4885RIPK3 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.